Related Experiment Videos
Editorial: "Dynamite pills" in the coronary-care unit?
The New England Journal of Medicine
|November 13, 1975
Summary
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Digitalis for treatment of congestive heart failure in patients in sinus rhythm.
The Cochrane database of systematic reviews·2004
Digitalis for treatment of congestive heart failure in patients in sinus rhythm.
The Cochrane database of systematic reviews·2001
Digitalis for treatment of congestive heart failure in patients in sinus rhythm.
The Cochrane database of systematic reviews·2001
Adverse effects of enalapril in the Studies of Left Ventricular Dysfunction (SOLVD). SOLVD Investigators.
American heart journal·1996
Dobutamine effects on systole and diastole in rats with myocardial infarction.
The American journal of the medical sciences·1995
Fibromyalgia.
The New England journal of medicine·2026
Health Care-Associated Infections in U.S. Hospitals, 2023 versus 2015.
The New England journal of medicine·2026
Extended Dual Antiplatelet Therapy for Multivessel Coronary Artery Disease.
The New England journal of medicine·2026
Continuous or Fixed-Duration Maintenance Therapy in Multiple Myeloma.
The New England journal of medicine·2026
Andes Virus - A Clinical Review.
The New England journal of medicine·2026
Platelet-Activating Anti-Platelet Factor 4 Disorders.
The New England journal of medicine·2026
Two undescribed bisabolane-type sesquiterpenoids from the endophytic fungus <i>Penicillium herquei</i>.
Journal of Asian natural products research·2026
The relevance of cannabinoid receptor 2 in the central nervous system: an update over the last 3 years.
Frontiers in behavioral neuroscience·2026
Do sigma-1 receptor agonists offer therapeutic promise for Alzheimer's disease?
Expert opinion on pharmacotherapy·2026
Protective Effects of Geraniol in Rheumatoid Arthritis Through Attenuation of Inflammation and Oxidative Stress.
Endocrine, metabolic & immune disorders drug targets·2026